What is the official website of MSD Belgium ?

The official website of MSD Belgium is http://www.msd-belgium.be.

What is MSD Belgium's cybersecurity risk score?

MSD Belgium has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Belgium experienced?

According to Rankiteo, MSD Belgium currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Belgium been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Belgium has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Belgium have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Belgium is not certified under SOC 2 Type 1.

Does MSD Belgium have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Belgium does not hold a SOC 2 Type 2 certification.

Does MSD Belgium comply with GDPR ?

According to Rankiteo, MSD Belgium is not listed as GDPR compliant.

Does MSD Belgium have PCI DSS certification ?

According to Rankiteo, MSD Belgium does not currently maintain PCI DSS compliance.

Does MSD Belgium comply with HIPAA ?

According to Rankiteo, MSD Belgium is not compliant with HIPAA regulations.

Does MSD Belgium have ISO 27001 certification ?

According to Rankiteo,MSD Belgium is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Belgium operate in ?

MSD Belgium operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Belgium have ?

MSD Belgium employs approximately 228 people worldwide.

Does MSD Belgium own any subsidiaries ?

MSD Belgium presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Belgium have ?

MSD Belgium's official LinkedIn profile has approximately 13,506 followers.

What is the NAICS classification code for MSD Belgium ?

MSD Belgium is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Belgium have a Crunchbase profile ?

No, MSD Belgium does not have a profile on Crunchbase.

Does MSD Belgium have a LinkedIn profile ?

Yes, MSD Belgium maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-belgium.

How many cybersecurity incidents has MSD Belgium experienced ?

As of August 5, 2026, Rankiteo reports that MSD Belgium has not experienced any cybersecurity incidents.

How many peer or competitor companies does MSD Belgium have ?

MSD Belgium has an estimated 5,722 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Belgium

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

MSD Belgium Vendor Cyber Rating & Cyber Score

msd-belgium.be

Add Your Compliance Badge

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of innovative products to improve human health. As an organization, our core values are driven by a desire to improve human life, achieve scientific excellence, operate with the highest standards of integrity, expand access to our products and employ a diverse workforce that values collaboration.

MSD Belgium A.I CyberSecurity Scoring

Scoring History

MSD Belgium

MSD Belgium CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

MSD Belgium Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Belgium

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Belgium in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Belgium in 2026.

Incident Types MSD Belgium vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Belgium in 2026.

Incident History - MSD Belgium (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Belgium Subsidiaries

Parent Company

MSD Belgium

Pharmaceutical Manufacturing

Website: http://www.msd-belgium.be

Company Size: 228

No subsidiary data available for this company.

Loading…

MSD Belgium Similar Companies

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

MSD Belgium CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-45537

SUMMARY

OpenSIPS is a Session Initiation Protocol (SIP) server implementation. In versions prior to 3.6.6 and 4.0.0-rc1, the construct_uri() function concatenates multiple URI components (protocol, username, domain, port, params) into a fixed 1024-byte global BSS buffer without any bounds checking. When a routing script calls construct_uri() with an attacker-controlled username, a combined component length exceeding 1024 bytes overflows the buffer, corrupting adjacent global data with attacker-controlled content. The overflow reaches disable_503_translation, a global flag controlling SIP 503 response handling, allowing an attacker to deterministically set the flag via the URI username and alter the server's routing behavior for subsequent messages. Because the same buffer is shared with contact_builder(), the overflow also corrupts that function's data, and without a memory sanitizer the adjacent globals are silently overwritten on every request containing a long username. This issue has been fixed in versions 3.6.6 and 4.0.0-rc1.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-18819

SUMMARY

A security vulnerability has been detected in RackTables up to 0.22.0/e5fff9f8aab339798ed47e8c6d7d977ed97a82bd. This vulnerability affects unknown code. The manipulation leads to cross-site request forgery. The attack is possible to be carried out remotely. The exploit has been disclosed publicly and may be used. The project maintainer confirms: "[I]t seems plausible, in that RackTables does not at this time have any CSRF prevention. You may assign a CVE ID to this, but there is no guarantee it will be handled in urgent, or even timely, manner, or at all."

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-18818

SUMMARY

A weakness has been identified in Ehco1996 django-sspanel up to 2023.12.26. This affects the function TicketDetailView of the file apps/sspanel/views.py of the component Support Ticket Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. The vendor was contacted early about this disclosure but did not respond in any way. This vulnerability only affects products that are no longer supported by the maintainer.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-70620

SUMMARY

Odysseus before commit 87babb5 contains a server-side request forgery vulnerability that allows admin-privileged attackers to direct the server to probe internal network resources by supplying arbitrary URLs to the embedding endpoint configuration without scheme, host, IP range, or DNS rebind validation. Attackers can submit loopback addresses, RFC 1918 ranges, or link-local addresses through the embedding endpoint API to partially read responses from cloud instance metadata services, internal APIs, and other hosts reachable from the server.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-70619

SUMMARY

Odysseus before commit bf325f6 contains a missing authorization vulnerability that allows authenticated non-admin users to manage server-wide embedding backend configuration by invoking endpoint management routes that verify session authentication but omit the admin authorization guard. Attackers can supply an attacker-controlled URL to overwrite the embedding backend persisted in the endpoint configuration file and process environment, causing all subsequent embedding operations including chat messages, RAG queries, memory entries, and vault text to be transmitted in plaintext to the attacker-controlled destination, or delete the endpoint configuration to deny embedding service to all users.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…